Target (drug, protein, antibody…) characterization on TMA
PROTEOGENIX has a division in charge of epidemiologic antibody characterization on Tissue MicroArray (TMA) offered in partnership with the company TRISTAR.
Our TMA’s gather more than 50 000 samples harshly selected for the quality of the tissues and for which we have an incomparable amount of clinical information. It is one of the largest collection in the world, with more than 120 tumor types available.
20 anatomical pathologists work in this division under GLP conditions or not to validate your antibodies on TMA in paraffin or frozen.
- perform cross reactivity studies of their targets in normal tissues (we have a special TMA containing all required tissues by the FDA)
- perform studies of target expression validation in normal tissues versus tumor tissues
- validate a diagnostic tool
- more basically study a target expression in all kind of tissues or sub-contract an immunohistochemistry study of any type.
The two main services with utility in target evaluation/validation are:
1) Large-scale analysis of target epidemiology in normal and cancerous formalin fixed tissues
2)?Evaluation of proprietary antibodies on frozen (and formalin fixed) tissues
1) Large-scale analysis of target epidemiology in normal and cancerous formalin fixed tissues
This group of projects aims at a full characterization of the expression of a target protein in normal and neoplastic human tissues. In addition, associations with tumor phenotype and prognosis are searched for in tumor entities with relevant fraction of “target positivity”.
These studies are optimal for early target evaluation. They provide a comprehensive understanding of normal tissue target expression and help secure important intellectual property in relevant cancer types as well as “niche tumors”. These studies may also constitute a basis for the necessary development of diagnostic tools paralleling drug development.
Stage 1 : It consists in developing an immunohistochemistry protocol in order to test your antibodies on TMAs containing normal tissues and tumor tissues.
Stage 2 : Analysis of normal tissues (76 different tissues, 8 donors) and multi tumor TMAs (120 tumors, 50 to 60 donors per tissue type)
Stage 3 : Additional analyses based on results of Stage 2
(A) Tumor specific TMAs with prognosis data
Type de cancer Nombre d’échantillons
Breast cancer 2200
Lung cancer 1400
Colon cancer 1400
Prostate cancer 2800
Pancreatic cancer 255
Bladder cancer 1000
Kidney cancer 350
Ovarian cancer 100
Endometrium cancer 180
Head & neck cancer 130
(B) Analysis of metastases
The TMAs stained are designed for comparative studies of target alteration in primary tumor vs. metastases.
2) Evaluation of proprietary antibodies on frozen (and formalin fixed) tissues
Aims :
- Identification of an antibody with good staining characteristics on paraffin embedded tissues (for large scale epidemiology studies, potentially also as a diagnostic tool)
- Identification of an antibody with good staining characteristics on frozen tissues (for epidemiology studies on frozen tissues)
- Determining optimal staining conditions for these antibodies considered suitable as therapeutic antibodies (necessary for FDA required cross reactivity studies)
- Limited molecular epidemiology analysis on frozen tissues normal tissue screening cancer screening
Stage 1 : IHC staining development protocol
Stage 2 : Normal tissue analysis (32 FDA required tissues from 3 different donors, GLP or not). This step can be performed on TMA of on large sections.